{"ok":true,"nota":{"id":"7b1bc7b372aeddad","slug":"en-melanoma-con-metastasis-cerebrales-un-analisis-de-sangre-ayuda-a-an-7b1bc7","titulo":"En melanoma con metástasis cerebrales, un análisis de sangre ayuda a anticipar quién responde","resumen":"Investigadores siguieron a 307 pacientes con melanoma que recibieron inmunoterapia, incluyendo a quienes tenían metástasis en el cerebro, que suelen quedar fuera de los ensayos. Buscaron marcadores en sangre y factores que predijeran la supervivencia.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Hassan, J., Little, M., Farkas, A., Mackay, S., Coupe, N., Middleton, M., Payne, M. J., Fairfax, B.","url":"https://www.medrxiv.org/content/10.64898/2026.10.19.26365947v1?rss=1","imagen":"/hoy/portada/7b1bc7b372aeddad","tema":"salud","subtemas":["melanoma","metástasis cerebrales","inmunoterapia","biomarcadores","supervivencia"],"entidades":["OxCITE","Universidad de Oxford","medRxiv"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-21T00:00:00.000Z","indexTs":"2026-10-21T22:39:37.287Z","hash":"2e654fe71b39503dbe57b5aeb2a1470ee955b738eb8803af624e0177cf201d47","tsa":{"time":"Oct 21 22:40:36 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"El dato central es que la sangre tomada antes del primer ciclo de tratamiento contiene señales que se asocian con cuánto vive el paciente. Para quien tiene un melanoma avanzado con compromiso cerebral, esto abre la puerta a elegir tratamientos con más criterio. Como se trata de un estudio observacional, hay que confirmar estas señales antes de usarlas para decidir por una persona.","quienFirma":"Universidad de Oxford (cohorte OxCITE)","confianza":"preprint","consulta":null},"sello":{"hash":"2e654fe71b39503dbe57b5aeb2a1470ee955b738eb8803af624e0177cf201d47","sello":"0958c417c729823f282d6f3b2eed65f604e2f370aa032fa936523311076079b8","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6573046,"aleatorio":"f71b3db032f12c8ae2d90f38aa37ddc03a4bd072f8a3317f2962e831c62e695d","tiempo":"2026-10-21T22:40:00.000Z"},"nist":{"cadena":2,"pulso":1993728,"salida":"DBB029F00A75EEAA9AF69BB0B3207AD12D5A4EDD2136CB35D25CB332980962472F1AFBB0B247EB7DF6BE52045BC8A63F1D14E2719075ECD2BA39DE673005A0E1","tiempo":"2026-10-21T22:39:00.000Z"},"noAntes":"2026-10-21T22:40:00.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 21 22:40:36 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Peripheral Biomarkers and Determinants of Survival for Patients with Melanoma Brain Metastasis Treated with Immune Checkpoint Blockade","descripcion":"Background Immune checkpoint blockade (ICB) has become the standard of treatment for metastatic melanoma (MM). However, patients with melanoma brain metastases (MBM) are often excluded from clinical trials. Here we analyse patients within the real-world OxCITE cohort receiving ICB treatment for metastatic melanoma, with a focus on MBM, aiming to discern outcomes, prognostic factors and peripheral biomarkers. Methods Patients eligible for ICB treatment were recruited prospectively. Demographic, clinical and radiological data were collected from electronic patient records. Plasma samples were collected prior to the first cycle of treatment for plasma proteomic analysis. Results 307 patients we","pubDate":"2026-10-21","url":"https://www.medrxiv.org/content/10.64898/2026.10.19.26365947v1?rss=1"},"indexado":"2026-10-21T22:39:37.287Z"}}